Short Interest in Oncolytics Biotech Inc. (NASDAQ:ONCY) Rises By 35.0%

Oncolytics Biotech Inc. (NASDAQ:ONCY) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,550,000 shares, a growth of 35.0% from the January 15th total of 2,630,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 3.0 days.

Oncolytics Biotech Stock Performance

NASDAQ ONCY traded down $0.00 during trading on Friday, hitting $0.77. The stock had a trading volume of 263,905 shares, compared to its average volume of 2,672,717. The stock has a 50 day simple moving average of $0.83 and a 200 day simple moving average of $0.96. Oncolytics Biotech has a one year low of $0.67 and a one year high of $1.53. The stock has a market capitalization of $61.39 million, a price-to-earnings ratio of -2.84 and a beta of 1.24.

Analyst Ratings Changes

A number of analysts recently commented on the company. Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Monday, February 3rd. Finally, Leede Financial downgraded Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th.

Hedge Funds Weigh In On Oncolytics Biotech

Several institutional investors and hedge funds have recently bought and sold shares of ONCY. Geode Capital Management LLC lifted its position in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after purchasing an additional 24,997 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after purchasing an additional 26,069 shares during the last quarter. Vantage Point Financial LLC acquired a new position in shares of Oncolytics Biotech in the 4th quarter valued at $27,000. National Bank of Canada FI lifted its stake in Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after acquiring an additional 42,955 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth about $90,000. 6.82% of the stock is owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.